ATE300529T1 - Imidazolderivate als raf-kinase-inhibitoren - Google Patents

Imidazolderivate als raf-kinase-inhibitoren

Info

Publication number
ATE300529T1
ATE300529T1 AT01967528T AT01967528T ATE300529T1 AT E300529 T1 ATE300529 T1 AT E300529T1 AT 01967528 T AT01967528 T AT 01967528T AT 01967528 T AT01967528 T AT 01967528T AT E300529 T1 ATE300529 T1 AT E300529T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
raf kinase
imidazole derivatives
migraine
pain
Prior art date
Application number
AT01967528T
Other languages
English (en)
Inventor
David Kenneth Dean
Andrew Kenneth Takle
David Matthew Wilson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0023193A external-priority patent/GB0023193D0/en
Priority claimed from GB0023208A external-priority patent/GB0023208D0/en
Priority claimed from GB0023197A external-priority patent/GB0023197D0/en
Priority claimed from GB0023196A external-priority patent/GB0023196D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE300529T1 publication Critical patent/ATE300529T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01967528T 2000-09-21 2001-09-19 Imidazolderivate als raf-kinase-inhibitoren ATE300529T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0023193A GB0023193D0 (en) 2000-09-21 2000-09-21 Compounds
GB0023208A GB0023208D0 (en) 2000-09-21 2000-09-21 Compounds
GB0023197A GB0023197D0 (en) 2000-09-21 2000-09-21 Compounds
GB0023196A GB0023196D0 (en) 2000-09-21 2000-09-21 Compouds
PCT/GB2001/004195 WO2002024680A1 (en) 2000-09-21 2001-09-19 Imidazole derivatives as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE300529T1 true ATE300529T1 (de) 2005-08-15

Family

ID=27447885

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01967528T ATE300529T1 (de) 2000-09-21 2001-09-19 Imidazolderivate als raf-kinase-inhibitoren

Country Status (21)

Country Link
US (2) US7199137B2 (de)
EP (1) EP1318992B1 (de)
JP (1) JP2004509882A (de)
KR (1) KR20030030027A (de)
CN (1) CN1471523A (de)
AT (1) ATE300529T1 (de)
AU (1) AU2001287901A1 (de)
BR (1) BR0114023A (de)
CA (1) CA2423154A1 (de)
CY (1) CY1105251T1 (de)
CZ (1) CZ2003793A3 (de)
DE (1) DE60112312T2 (de)
DK (1) DK1318992T3 (de)
ES (1) ES2242767T3 (de)
HU (1) HUP0301181A2 (de)
IL (1) IL154949A0 (de)
MX (1) MXPA03002449A (de)
NO (1) NO20031270L (de)
PL (1) PL361397A1 (de)
PT (1) PT1318992E (de)
WO (1) WO2002024680A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189745B1 (en) 1999-11-22 2007-03-13 Smithkline Beecham Corporation Compounds
DE60103136T2 (de) * 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazolderivate als Raf-Kinase Inhibitoren
WO2002039954A2 (en) * 2000-11-20 2002-05-23 Smithkline Beecham Corporation Novel compounds
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121490D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
EP1432703A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
EP1432699A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Pyridylfurane und -pyrrole als raf-kinasehemmer
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
WO2003086467A1 (en) * 2002-04-08 2003-10-23 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
AR040847A1 (es) 2002-08-09 2005-04-20 Astrazeneca Ab 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos
TW200424183A (en) * 2002-08-09 2004-11-16 Nps Pharma Inc New compounds
WO2004014902A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
BRPI0313763B8 (pt) 2002-08-19 2021-05-25 4325231 Canada Inc imidazóis 2,4,5-trissubstituídos, seus usos, e composições farmacêutica e anti-microbiana
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
US20050250837A1 (en) * 2002-10-18 2005-11-10 D Mello Santosh R Use of C-Raf inhibitors for the treatment of neurodegenerative diseases
US20090264494A1 (en) * 2002-10-18 2009-10-22 Board Of Regents, The University Of Texas System Use of neuroprotective 3-substituted indolone compositions
WO2004090545A2 (en) * 2003-04-14 2004-10-21 Novartis Ag Methods for treating proliferative diseases and for monitoring the effectiveness of treatment of proliferative diseases
CA2540518A1 (en) * 2003-10-02 2005-04-07 Irm Llc Compounds and compositions as protein kinase inhibitors
DK1692113T3 (en) * 2003-11-14 2018-01-08 Lorus Therapeutics Inc ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CN101248072B (zh) 2005-05-25 2013-01-23 劳洛斯治疗公司 2-吲哚基咪唑并[4,5-d]菲咯啉衍生物及其在癌症治疗中的用途
JP5512125B2 (ja) 2005-09-12 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
AU2007317306B2 (en) * 2006-11-08 2012-06-14 The Regents Of The University Of Michigan SPINK1 as a prostate cancer marker and uses thereof
BRPI0806365B8 (pt) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
ES2376509T3 (es) 2007-07-06 2012-03-14 The Regents Of The University Of Michigan Reordenamientos de genes mipol 1-etv1.
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
WO2009045440A1 (en) 2007-10-01 2009-04-09 Lixte Biotechnology Holdings, Inc. Hdac inhibitors
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US8058268B2 (en) 2008-08-01 2011-11-15 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
WO2011034906A2 (en) * 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2786424A1 (en) * 2010-01-08 2011-07-14 Ruga Corporation Raf kinase inhibitors
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
EP2700403B1 (de) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutikum für tumor
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
WO2013022766A1 (en) * 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
CN103159735B (zh) * 2011-12-10 2015-12-09 通化济达医药有限公司 取代的咪唑激酶抑制剂
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
US20150232452A1 (en) * 2012-09-19 2015-08-20 Ruga Corporation Novel raf kinase inhibitors
WO2014153464A2 (en) 2013-03-20 2014-09-25 Lorus Therapeutics Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
CA2909160C (en) 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
EP3046557A1 (de) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in kombination mit mapk-signalweg
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
CN105764511B (zh) 2013-10-04 2019-01-11 艾普托斯生物科学公司 用于治疗癌症的组合物和方法
WO2018107004A1 (en) 2016-12-08 2018-06-14 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
CN111417395A (zh) 2017-10-30 2020-07-14 艾普托斯生物科学公司 用于治疗癌症的芳基咪唑
CN108484587A (zh) * 2018-06-03 2018-09-04 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
WO2022249192A1 (en) * 2021-05-27 2022-12-01 Ramot At Tel-Aviv University Ltd. Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
AU7629594A (en) * 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
CA2224563A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
JP2000504023A (ja) 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
EP0906307B1 (de) * 1996-06-10 2005-04-27 Merck & Co., Inc. Substituierte imidazole mit cytokinin-inhibirender wirkung
WO1997048672A2 (en) 1996-06-21 1997-12-24 Allergan Sales, Inc. Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
WO1998016227A1 (en) 1996-10-15 1998-04-23 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
BR9712720A (pt) 1996-10-30 1999-10-26 Schering Corp Derivados de piperazina como antagÈnicos de neurocinina
ATE257703T1 (de) 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
EP1031572A4 (de) 1997-11-14 2001-09-19 Sankyo Co Pyridylpyrrol-derivate
ATE355856T1 (de) 1998-07-30 2007-03-15 Point Biomedical Corp Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln

Also Published As

Publication number Publication date
BR0114023A (pt) 2004-02-03
CZ2003793A3 (cs) 2004-04-14
WO2002024680A1 (en) 2002-03-28
IL154949A0 (en) 2003-10-31
DK1318992T3 (da) 2005-11-21
KR20030030027A (ko) 2003-04-16
HUP0301181A2 (en) 2007-02-28
DE60112312T2 (de) 2005-12-29
CY1105251T1 (el) 2010-03-03
US20070135433A1 (en) 2007-06-14
PT1318992E (pt) 2005-11-30
MXPA03002449A (es) 2003-06-19
US20040038964A1 (en) 2004-02-26
EP1318992A1 (de) 2003-06-18
CN1471523A (zh) 2004-01-28
PL361397A1 (en) 2004-10-04
EP1318992B1 (de) 2005-07-27
NO20031270D0 (no) 2003-03-19
DE60112312D1 (de) 2005-09-01
NO20031270L (no) 2003-05-19
AU2001287901A1 (en) 2002-04-02
JP2004509882A (ja) 2004-04-02
CA2423154A1 (en) 2002-03-28
ES2242767T3 (es) 2005-11-16
US7199137B2 (en) 2007-04-03

Similar Documents

Publication Publication Date Title
DE60112312D1 (de) Imidazolderivate als raf-kinase-inhibitoren
ATE362929T1 (de) Pyridinderivate als inhibitoren der raf-kinase
DE60319158D1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
ATE408601T1 (de) Fredericamycin-derivate
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
NO20091618L (no) Bicykliske triazoler som proteinkinasemodulatorer
DE60318177D1 (de) Rho-kinase inhibitoren
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
DE60228098D1 (de) Pyridin-substituierte furanderivate als raf-kinase inhibitoren
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
DE60214019D1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
DE60305053D1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
DE60213798D1 (de) Carbolinderivate als pdev inhibitoren
BRPI0508881A (pt) derivados de imidazol
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1318992

Country of ref document: EP

REN Ceased due to non-payment of the annual fee